A Prospective Study on [68Ga]-PSMA PET/CT Imaging in Newly Diagnosed Intermediate- and High-Risk Prostate Cancer
Objective(s): Prostate-specific membrane antigen (PSMA) ligand positron emission tomography/computed tomography (PET/CT) is an emerging modality to detect metastatic disease in patients with prostate cancer (PCa). This prospective study aimed to evaluate the role of [68Ga]-PSMA PET/CT in the initial...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Mashhad University of Medical Sciences
2021-07-01
|
| Series: | Asia Oceania Journal of Nuclear Medicine and Biology |
| Subjects: | |
| Online Access: | https://aojnmb.mums.ac.ir/article_17137_21e17ef526a522a786ca9561ba34257c.pdf |
| _version_ | 1819085896089075712 |
|---|---|
| author | Sara Harsini Babak Fallahi Najme Karamzade ziarati Ali Razi Erfan Amini Alireza Emami Ardekani Armaghan Fard Esfehani Mehdi Kardoust Parizi saeed farzanehfar Davood Beiki |
| author_facet | Sara Harsini Babak Fallahi Najme Karamzade ziarati Ali Razi Erfan Amini Alireza Emami Ardekani Armaghan Fard Esfehani Mehdi Kardoust Parizi saeed farzanehfar Davood Beiki |
| author_sort | Sara Harsini |
| collection | DOAJ |
| description | Objective(s): Prostate-specific membrane antigen (PSMA) ligand positron emission tomography/computed tomography (PET/CT) is an emerging modality to detect metastatic disease in patients with prostate cancer (PCa). This prospective study aimed to evaluate the role of [68Ga]-PSMA PET/CT in the initial workup of intermediate and high-risk PCa .Methods: Twenty-five patients with newly transrectal ultrasound biopsy-proven, untreated intermediate- and high-risk PCa (mean age, 68.5±6.2 years; range 55–83 years) were enrolled in this prospective study between September 2018 and June 2020 and underwent a [68Ga]-PSMA PET/CT examination. All images were analyzed both visually and semiquantitatively by measuring the maximum standardized uptake value (SUVmax) of the primary prostatic tumor and metastatic lesions. The diagnostic sensitivity of [68Ga]-PSMA PET/CT for the diagnosis of PCa was established by histopathology as the reference standard. The associations between SUVmax of the primary tumors and prostate-specific antigen (PSA) levels, Gleason scores (GSs), and metastatic extent of the disease were studied.Results: All patients had a positive [68Ga]-PSMA PET/CT exam. Seventeen patients (58%) showed [68Ga]-PSMA avidity in both prostate lobes and 8 (32%) had unilateral uptake. SUVmax in the primary tumor significantly correlated with serum PSA values (r=0.57, P=0.003). PSMA PET/CT depicted regional lymph node metastases in 32% of patients, distant lymph node metastases in 20%, osseous metastases in 16% and pulmonary metastases in 8% of patients. Sixty percent of PSMA-positive bone metastases and 21.4% of intraprostatic tumoral lesions were missed on the contemporaneous bone scintigraphy and magnetic resonance imaging, respectively.Conclusion: [68Ga]-PSMA PET/CT shows promise as a valuable imaging modality with high diagnostic sensitivity in the setting of intermediate and high-risk PCa. Moreover, the SUVmax of the primary tumor has a positive correlation with PSA levels at the time of the scan. |
| first_indexed | 2024-12-21T21:11:38Z |
| format | Article |
| id | doaj.art-6596208390254f429801fa7a002b1c5f |
| institution | Directory Open Access Journal |
| issn | 2322-5718 2322-5726 |
| language | English |
| last_indexed | 2024-12-21T21:11:38Z |
| publishDate | 2021-07-01 |
| publisher | Mashhad University of Medical Sciences |
| record_format | Article |
| series | Asia Oceania Journal of Nuclear Medicine and Biology |
| spelling | doaj.art-6596208390254f429801fa7a002b1c5f2022-12-21T18:50:08ZengMashhad University of Medical SciencesAsia Oceania Journal of Nuclear Medicine and Biology2322-57182322-57262021-07-019210111010.22038/aojnmb.2020.52375.135817137A Prospective Study on [68Ga]-PSMA PET/CT Imaging in Newly Diagnosed Intermediate- and High-Risk Prostate CancerSara Harsini0Babak Fallahi1Najme Karamzade ziarati2Ali Razi3Erfan Amini4Alireza Emami Ardekani5Armaghan Fard Esfehani6Mehdi Kardoust Parizi7saeed farzanehfar8Davood Beiki9Research Center for Nuclear Medicine, Tehran University of Medical sciences, Tehran, IranResearch Center for Nuclear Medicine, Tehran University of Medical sciences, Tehran, IranResearch Center for Nuclear Medicine, Tehran University of Medical sciences, Tehran, IranDepartment of Urology, Tehran University of Medical Sciences, Tehran, IranUro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, IranResearch Center for Nuclear Medicine, Tehran University of Medical sciences, Tehran, IranResearch Center for Nuclear Medicine, Tehran University of Medical sciences, Tehran, IranDepartment of Urology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, IranDepartment of Nuclear Medicine, Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, IranResearch Center for Nuclear Medicine, Tehran University of Medical sciences, Tehran, IranObjective(s): Prostate-specific membrane antigen (PSMA) ligand positron emission tomography/computed tomography (PET/CT) is an emerging modality to detect metastatic disease in patients with prostate cancer (PCa). This prospective study aimed to evaluate the role of [68Ga]-PSMA PET/CT in the initial workup of intermediate and high-risk PCa .Methods: Twenty-five patients with newly transrectal ultrasound biopsy-proven, untreated intermediate- and high-risk PCa (mean age, 68.5±6.2 years; range 55–83 years) were enrolled in this prospective study between September 2018 and June 2020 and underwent a [68Ga]-PSMA PET/CT examination. All images were analyzed both visually and semiquantitatively by measuring the maximum standardized uptake value (SUVmax) of the primary prostatic tumor and metastatic lesions. The diagnostic sensitivity of [68Ga]-PSMA PET/CT for the diagnosis of PCa was established by histopathology as the reference standard. The associations between SUVmax of the primary tumors and prostate-specific antigen (PSA) levels, Gleason scores (GSs), and metastatic extent of the disease were studied.Results: All patients had a positive [68Ga]-PSMA PET/CT exam. Seventeen patients (58%) showed [68Ga]-PSMA avidity in both prostate lobes and 8 (32%) had unilateral uptake. SUVmax in the primary tumor significantly correlated with serum PSA values (r=0.57, P=0.003). PSMA PET/CT depicted regional lymph node metastases in 32% of patients, distant lymph node metastases in 20%, osseous metastases in 16% and pulmonary metastases in 8% of patients. Sixty percent of PSMA-positive bone metastases and 21.4% of intraprostatic tumoral lesions were missed on the contemporaneous bone scintigraphy and magnetic resonance imaging, respectively.Conclusion: [68Ga]-PSMA PET/CT shows promise as a valuable imaging modality with high diagnostic sensitivity in the setting of intermediate and high-risk PCa. Moreover, the SUVmax of the primary tumor has a positive correlation with PSA levels at the time of the scan.https://aojnmb.mums.ac.ir/article_17137_21e17ef526a522a786ca9561ba34257c.pdfprostate cancerpsma pet/ctprimary staging |
| spellingShingle | Sara Harsini Babak Fallahi Najme Karamzade ziarati Ali Razi Erfan Amini Alireza Emami Ardekani Armaghan Fard Esfehani Mehdi Kardoust Parizi saeed farzanehfar Davood Beiki A Prospective Study on [68Ga]-PSMA PET/CT Imaging in Newly Diagnosed Intermediate- and High-Risk Prostate Cancer Asia Oceania Journal of Nuclear Medicine and Biology prostate cancer psma pet/ct primary staging |
| title | A Prospective Study on [68Ga]-PSMA PET/CT Imaging in Newly Diagnosed Intermediate- and High-Risk Prostate Cancer |
| title_full | A Prospective Study on [68Ga]-PSMA PET/CT Imaging in Newly Diagnosed Intermediate- and High-Risk Prostate Cancer |
| title_fullStr | A Prospective Study on [68Ga]-PSMA PET/CT Imaging in Newly Diagnosed Intermediate- and High-Risk Prostate Cancer |
| title_full_unstemmed | A Prospective Study on [68Ga]-PSMA PET/CT Imaging in Newly Diagnosed Intermediate- and High-Risk Prostate Cancer |
| title_short | A Prospective Study on [68Ga]-PSMA PET/CT Imaging in Newly Diagnosed Intermediate- and High-Risk Prostate Cancer |
| title_sort | prospective study on 68ga psma pet ct imaging in newly diagnosed intermediate and high risk prostate cancer |
| topic | prostate cancer psma pet/ct primary staging |
| url | https://aojnmb.mums.ac.ir/article_17137_21e17ef526a522a786ca9561ba34257c.pdf |
| work_keys_str_mv | AT saraharsini aprospectivestudyon68gapsmapetctimaginginnewlydiagnosedintermediateandhighriskprostatecancer AT babakfallahi aprospectivestudyon68gapsmapetctimaginginnewlydiagnosedintermediateandhighriskprostatecancer AT najmekaramzadeziarati aprospectivestudyon68gapsmapetctimaginginnewlydiagnosedintermediateandhighriskprostatecancer AT alirazi aprospectivestudyon68gapsmapetctimaginginnewlydiagnosedintermediateandhighriskprostatecancer AT erfanamini aprospectivestudyon68gapsmapetctimaginginnewlydiagnosedintermediateandhighriskprostatecancer AT alirezaemamiardekani aprospectivestudyon68gapsmapetctimaginginnewlydiagnosedintermediateandhighriskprostatecancer AT armaghanfardesfehani aprospectivestudyon68gapsmapetctimaginginnewlydiagnosedintermediateandhighriskprostatecancer AT mehdikardoustparizi aprospectivestudyon68gapsmapetctimaginginnewlydiagnosedintermediateandhighriskprostatecancer AT saeedfarzanehfar aprospectivestudyon68gapsmapetctimaginginnewlydiagnosedintermediateandhighriskprostatecancer AT davoodbeiki aprospectivestudyon68gapsmapetctimaginginnewlydiagnosedintermediateandhighriskprostatecancer AT saraharsini prospectivestudyon68gapsmapetctimaginginnewlydiagnosedintermediateandhighriskprostatecancer AT babakfallahi prospectivestudyon68gapsmapetctimaginginnewlydiagnosedintermediateandhighriskprostatecancer AT najmekaramzadeziarati prospectivestudyon68gapsmapetctimaginginnewlydiagnosedintermediateandhighriskprostatecancer AT alirazi prospectivestudyon68gapsmapetctimaginginnewlydiagnosedintermediateandhighriskprostatecancer AT erfanamini prospectivestudyon68gapsmapetctimaginginnewlydiagnosedintermediateandhighriskprostatecancer AT alirezaemamiardekani prospectivestudyon68gapsmapetctimaginginnewlydiagnosedintermediateandhighriskprostatecancer AT armaghanfardesfehani prospectivestudyon68gapsmapetctimaginginnewlydiagnosedintermediateandhighriskprostatecancer AT mehdikardoustparizi prospectivestudyon68gapsmapetctimaginginnewlydiagnosedintermediateandhighriskprostatecancer AT saeedfarzanehfar prospectivestudyon68gapsmapetctimaginginnewlydiagnosedintermediateandhighriskprostatecancer AT davoodbeiki prospectivestudyon68gapsmapetctimaginginnewlydiagnosedintermediateandhighriskprostatecancer |